NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Revvity, Inc. (RVTY) Stock Analysis

Revvity, Inc. (RVTY) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

RVTY

$130.22

−$0.41 (−0.31%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RVTY with… →

RVTY Key Statistics

As of Sep 4, 2026
Trading
Open
$130.03
Previous Close
$130.63
Day's Range
129.56–131.70
52-Week Range
81.22–133.00
Volume
1.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.09
Valuation
Market Cap
$14.53B
P/E Ratio
62.61
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.10
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.73
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.99
EPS (ttm)Profit attributable to each share over the last twelve months.
2.08
Financials (FY)
Revenue (FY)
$2.86B+3.67%
Net Income (FY)
$241.20M−10.79%
Profit marginThe share of revenue left as profit after all costs and taxes.
8.16%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
111.59M
1-Year Return
+52.37%
Dividend and dates
Dividend
$0.28+0.21%
Ex-Dividend Date
October 23, 2026
Earnings Date
October 26, 2026estimated
Avg Volume
1.52M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RVTY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.87%
2025−13.07%
2024+2.37%
2023−21.87%
2022−30.13%
2021+40.37%
2020+48.20%
2019+24.01%
2018+7.80%
2017+40.85%
2016 (partial year)−4.35%

As of September 4, 2026.

RVTY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.86B$241.20M8.4%
2024$2.76B$270.39M9.8%
2023$2.75B$693.09M25.2%
2022$3.31B$569.18M17.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.86B$1.56B$356.64M$241.20M8.4%
2024$2.76B$1.54B$346.74M$270.39M9.8%
2023$2.75B$1.54B$300.56M$693.09M25.2%
2022$3.31B$1.99B$742.70M$569.18M17.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RVTY Dividend History

$0.28+0.0% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.213—
2025$0.284+0.0%
2024$0.284+0.0%
2023$0.284+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.213—
2025$0.284+0.0%
2024$0.284+0.0%
2023$0.284+0.0%
2022$0.284+0.0%
2021$0.284+0.0%
2020$0.284+0.0%
2019$0.284+0.0%
2018$0.284+0.0%
2017$0.284+300.0%
2016$0.071—

Most recent payment: $0.07 per share, ex-dividend July 17, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

RVTY Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricRVTYDiagnostics & Research medianvs median
P/E62.6133.0889% above
P/S ratio4.994.990% above
Profit margin8.16%0.00%8.2 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Revvity, Inc. (RVTY) is capitalised at $14.53B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 11,000.

Over the past 52 weeks the price has ranged from $81.22 to $133.00. RVTY last closed at $130.22 on September 4, 2026. That is −$0.41 (−0.31%) against the previous close. The latest close sits 60.33% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.86B. Against the prior fiscal year total of $2.76B, that is a change of +3.67%. Net income for the same year was $241.20M. That is −10.79% against the prior fiscal year. Profit margin runs at 8.16%. That is 8.2 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 2.08.

Across the 4 fiscal years on file, revenue moves from $3.31B in 2022 to $2.86B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

RVTY trades at a trailing price-to-earnings ratio of 62.61. That is 89.27% above the Diagnostics & Research median of 33.08. The forward P/E on file is 22.1. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.73. Measured against sales, the shares trade at 4.99 times revenue. On price-to-sales that is 0% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +52.37%. Across 10 years the annualized return works out at +9.63%. The reported beta is 1.09. Daily returns over the trailing 10 years annualize to a volatility of 31.11%.

Growth & Income

Shareholders receive a dividend, yielding 0.21% on the latest price. That is 0.6 percentage points below the Diagnostics & Research median yield of 0.76%. The indicated annual rate is $0.28 a share. The ex-dividend date on file is October 23, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $0.21 a share. The year before, 2025, totalled $0.28 a share.

The strongest complete calendar year on file is 2020 at +48.20%; the weakest is 2022 at −30.13%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +34.87% year to date.

Peer Comparison

Revvity, Inc. (RVTY) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Revvity, Inc. RVTY $14.53B 62.6
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Revvity, Inc. trades at a P/E of 62.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Visit website →